Highlighting Bispecific Use Across Multiple Myeloma Indications
Shebli Atrash, MD, stated that MRD should be considered carefully as an end point, given potential recurrence despite MRD negativity.
Previous Post
AAIC Presentation Highlights Improved Efficacy and Safety With Lecanemab Subcutaneous Autoinjector
Next Post
Uterine conditions
📢
Advertisement
300x250 Banner
Recent Content
COPD Biologics: Early Treatment Insights
Pulmonology • 2 hours ago
Antihypertensive Medication Guidelines
Cardiology • 4 hours ago
Juvenile Arthritis Care Transition
Rheumatology • 6 hours ago